Senti Biosciences Unveils Promising Phase 1 Trial Data

Senti Biosciences ( (SNTI) ) just unveiled an update.

On April 28, 2025, Senti Biosciences announced preliminary data from a Phase 1 clinical trial of SENTI-202, a novel CAR NK cell therapy for relapsed/refractory hematologic malignancies, including AML. This data, presented at the AACR Annual Meeting 2025, showed positive preliminary efficacy and supports the potential of SENTI-202 as a first-in-class treatment option, which could significantly impact the company’s market positioning and offer new hope for stakeholders dealing with these aggressive cancers.

Spark’s Take on SNTI Stock

According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.

Senti Biosciences faces significant financial instability, as reflected in its low financial performance score. Despite short-term positive market momentum, the company’s valuation remains unattractive due to negative earnings. Recent corporate appointments are positive, but insufficient to offset underlying financial weaknesses.

To see Spark’s full report on SNTI stock, click here.

More about Senti Biosciences

Senti Biosciences operates in the biotechnology industry, focusing on developing innovative cell therapies. The company specializes in creating off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapies targeting difficult-to-treat cancers, such as acute myeloid leukemia (AML).

YTD Price Performance: 31.23%

Average Trading Volume: 30,205

Technical Sentiment Signal: Sell

Current Market Cap: $129.9M

For detailed information about SNTI stock, go to TipRanks’ Stock Analysis page.